ArticleJournal of molecular neuroscience : MN2026
PRDX6 as a Ferroptosis-Related Hub Gene in the Entorhinal Cortex of Alzheimer's Disease: A Multidimensional Bioinformatics and Experimental Validation Study.
Article in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Peroxiredoxin-Mediated Redox Regulation in Neurons: From Neurite Development to Degeneration.Antioxidants (Basel, Switzerland) · 2026Review
- Metabolic cell death networks in Alzheimer's disease: mechanistic links and therapeutic perspectives of ferroptosis, cuproptosis, and disulfidptosis.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Ferroptosis, an iron-dependent regulated cell death form, is a key pathogenic mechanism in Alzheimer's disease (AD), especially in the entorhinal cortex, a brain region selectively vulnerable to early AD neuropathology. This study aimed to identify peroxiredoxin 6 (PRDX6) as a novel ferroptosis-related hub gene in the entorhinal cortex and validate its diagnostic and therapeutic potential in AD. Gene expression datasets (GSE138852, GSE5281, GSE48350, GSE118553) from the Gene Expression Omnibus (GEO) and ferroptosis-related genes (FRGs) from FerrDb were analyzed. Differential expressed genes (DEGs) were identified using Limma (|log2FC| > 1, P < 0.05), followed by Weighted Gene Coexpression Network Analysis (WGCNA) to delineate AD-associated modules. Machine learning approaches (LASSO and random forest) were employed to screen candidate hub genes, and CIBERSORT was utilized to assess correlations with immune cell infiltration. Single-cell RNA sequencing (scRNA-seq) data from GSE138852 mapped gene distribution across entorhinal cortex cell populations. Validation included analyses in the Alzdata database, receiver operating characteristic (ROC) curves for diagnostic accuracy, and Western blot assays in Aβ
Indexed as
Identifiers
41634496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.